Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 18/20 | 1.00 |
| ▸ | GIPR | P48546 | 17/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2649467 | 0.92 | GCGR (0.84) | GCGRGIPR | |
| SCHEMBL2654058 | 0.92 | GCGR (0.84) | GCGRGIPRMAPTMEN1POLB | |
| SCHEMBL2648190 | 0.90 | GCGR (1.00) | GCGRGIPR | |
| SCHEMBL2648554 | 0.90 | GCGR (1.00) | GCGRGIPR | |
| SCHEMBL2647393 | 0.89 | GCGR (0.87) | GCGRGIPR | |
| SCHEMBL2647721 | 0.87 | GCGR (0.81) | GCGRGIPRMAPTPOLB | |
| SCHEMBL2647719 | 0.87 | GCGR (0.81) | GCGRGIPRMAPTPOLB | |
| SCHEMBL2647725 | 0.86 | GCGR (0.75) | GCGRGIPRMAPTMEN1KMT2A | |
| SCHEMBL2647099 | 0.85 | GCGR (0.92) | GCGRGIPR | |
| SCHEMBL2656182 | 0.85 | GCGR (0.73) | GCGRGIPRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256175-A1 | Novel glucagon antagonists/inverse agonists | LAU JESPER | 2005-11-17 | — | — | US | disclosed |
| US-6881746-B2 | Glucagon antagonists/inverse agonists | NOVO NORDICK A/S (DK) | 2005-04-19 | — | — | US | disclosed |
| EP-1519723-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004002480-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002480-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256175-A1 | Novel glucagon antagonists/inverse agonists | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885MAPT 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.